Compass Pathways PLC Sponsored ADR $CMPS Stock Holdings Lifted by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 169.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 424,800 shares of the company’s stock after buying an additional 266,908 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Compass Pathways were worth $2,931,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of CMPS. Advisory Services Network LLC acquired a new stake in Compass Pathways during the third quarter worth about $41,000. Parkman Healthcare Partners LLC acquired a new position in Compass Pathways in the third quarter valued at approximately $573,000. Mercer Global Advisors Inc. ADV acquired a new position in Compass Pathways in the third quarter valued at approximately $118,000. Millennium Management LLC grew its holdings in shares of Compass Pathways by 39.9% during the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares during the last quarter. Finally, Jain Global LLC bought a new position in shares of Compass Pathways during the third quarter valued at approximately $1,010,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of NASDAQ CMPS opened at $5.52 on Wednesday. Compass Pathways PLC Sponsored ADR has a 12-month low of $2.25 and a 12-month high of $8.90. The company has a market cap of $530.03 million, a PE ratio of -1.79 and a beta of 1.90. The stock has a 50 day simple moving average of $6.58 and a 200-day simple moving average of $6.31. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.55.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). On average, equities research analysts forecast that Compass Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Royal Bank Of Canada raised their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. HC Wainwright increased their target price on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Canaccord Genuity Group cut their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, March 26th. Finally, Compass Point set a $15.00 price objective on shares of Compass Pathways in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.63.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.